Could a menopause drug cool hot flashes in men with prostate cancer?

NCT ID NCT06972875

Recruiting now Symptom relief Sponsor: University of Vermont Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called fezolinetant, already approved for hot flashes in menopausal women, to see if it can reduce hot flashes in men with prostate cancer who are on hormone-lowering therapy. About 32 men will take the drug daily for 28 days. The goal is to measure how much hot flash symptoms improve and to check for any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fezolinetant
What this could lead to: If it works, this could offer a non-hormonal option to manage hot flashes in men undergoing prostate cancer treatment, improving daily comfort and treatment adherence.
What could go wrong: This is a small, early-phase study with only 32 participants, so results may not apply broadly. The drug is approved for women but not yet proven safe or effective in men.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANDROGEN DEPRIVATION THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hot Flashes prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANDROGEN DEPRIVATION THERAPY PROSTATE CA

Contacts and locations

Locations

University of Vermont Medical Center
RECRUITING

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.